FTC says that Breathometer marketing was deceptive with claims that lacked scientific evidence and orders company to offer full refunds
Consumers spent more than $5 million on Breathometer devices they were told would accurately measure their blood alcohol content, but the marketing was deceptive …
Context & Ripple Effects
The Breathometer order slots into an FTC enforcement arc against consumer products whose marketing outruns their science. Two years earlier, the agency hit Lumosity with a $2M settlement over 'brain training' ads that promised cognitive benefits without evidence — the same template of a consumer device selling a measurable health claim it couldn't back.
What distinguishes this case is the remedy: rather than a fine, the FTC ordered full refunds on more than $5M in device sales, putting the entire purchase price at risk when accuracy claims lack substantiation.
First-order effects
- Breathometer buyers become eligible for full refunds, making the company's $5M-plus revenue effectively contingent on proving its blood-alcohol accuracy claims or abandoning them.
Second-order effects
- Rival consumer health-device makers now price unsubstantiated accuracy claims at total-revenue risk, not just ad-spend risk — a materially higher bar than the flat penalties in cases like Lumosity's.
Third-order effects
- If the refund remedy becomes standard, the FTC's consumer-tech playbook converges with its supplement and review-integrity work — from the first fake paid Amazon reviews case to the TurboTax 'free' ruling — toward requiring clinical-grade substantiation for any quantified health or performance claim marketed to consumers.
The trend: Consumer wellness hardware is being held to the same evidence-substantiation standard the FTC has long applied to supplements, with refunds replacing fines as the deterrent.